Ed Clarke
Overview
Explore the profile of Ed Clarke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Butcher R, Jarju S, Obayemi D, Bashorun A, Vasileva H, Bransbury-Hare H, et al.
BMC Infect Dis
. 2023 Jul;
23(1):471.
PMID: 37442966
Background: The prevalence of sexually transmitted infections (STIs) in sub-Saharan Africa is poorly described. We aimed to determine the prevalence of five treatable STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis,...
12.
Haidara F, Umesi A, Sow S, Ochoge M, Diallo F, Imam A, et al.
N Engl J Med
. 2023 May;
388(21):1942-1955.
PMID: 37224196
Background: An effective, affordable, multivalent meningococcal conjugate vaccine is needed to prevent epidemic meningitis in the African meningitis belt. Data on the safety and immunogenicity of NmCV-5, a pentavalent vaccine...
13.
Wilson R, Leigh L, Bah H, Larson H, Clarke E
Vaccine
. 2023 May;
41(24):3647-3654.
PMID: 37173265
This qualitative study using in-depth interviews and focus group discussions is the first to investigate HPV vaccination in The Gambia; it provides an in-depth analysis of uptake, knowledge, and perceptions...
14.
Jarju S, Senghore E, Brotherton H, Affleck L, Saidykhan A, Krubally E, et al.
Gates Open Res
. 2023 Mar;
6:148.
PMID: 36726685
In many countries, non-pharmaceutical interventions to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission resulted in significant reductions in other respiratory viruses. However, similar data from Africa are limited....
15.
Adigweme I, Futa A, Saidy-Jah E, Edem B, Akpalu E, Dibbasey T, et al.
Lancet Infect Dis
. 2023 Jan;
23(5):609-620.
PMID: 36638819
Background: Three pneumococcal conjugate vaccines (PCVs) are currently licensed and WHO prequalified for supply by UN agencies. Here, we aimed to investigate the safety and immunogenicity of SIIPL-PCV compared with...
16.
Adigweme I, Akpalu E, Yisa M, Donkor S, Jarju L, Danso B, et al.
Trials
. 2022 Sep;
23(1):775.
PMID: 36104719
Background: New strategies to increase measles and rubella vaccine coverage, particularly in low- and middle-income countries, are needed if elimination goals are to be achieved. With this regard, measles and...
17.
18.
Costa-Martins A, Mane K, Lindsey B, Ogava R, Castro I, Jagne Y, et al.
Cell Rep Med
. 2022 Mar;
3(2):100516.
PMID: 35243419
[This corrects the article DOI: 10.1016/j.xcrm.2021.100465.].
19.
Mackenzie G, Osei I, Salaudeen R, Secka O, DAlessandro U, Clarke E, et al.
Trials
. 2022 Jan;
23(1):39.
PMID: 35033180
Background: Pneumococcal conjugate vaccines (PCVs) effectively prevent pneumococcal disease, but the global impact of pneumococcal vaccination is hampered by its cost. The evaluation of reduced dose schedules of PCV includes...
20.
Costa-Martins A, Mane K, Lindsey B, Ogava R, Castro I, Jagne Y, et al.
Cell Rep Med
. 2022 Jan;
2(12):100465.
PMID: 35028607
In children lacking influenza-specific adaptive immunity, upper respiratory tract innate immune responses may influence viral replication and disease outcome. We use trivalent live attenuated influenza vaccine (LAIV) as a surrogate...